AKTX earnings date and last-quarter result: next report 2026-08-18, last quarter miss, P/E -0.01. Updated 2026-07-23.
Akari Therapeutics (AKTX) Research Hub
Akari Therapeutics (AKTX) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 7.63 USD (-7.29%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -0.01, market cap 0.01B. This hub links to the full technical, earnings and options research available for AKTX.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 7.63 USD (-7.29%) |
| 52-week range | 6.91 USD – 15.5 USD |
| Trend regime | Range |
| 14-day RSI | 45.9 (Neutral) |
| Trailing P/E | -0.01 |
| Market cap | 0.01B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-18 |
Available research for AKTX
Covered Call on AKTX: how it works, illustrative setup around the real 7.63 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on AKTX: how it works, illustrative setup around the real 7.63 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on AKTX: how it works, illustrative setup around the real 7.63 USD price, max profit/loss, breakeven and when to use it. Educational.
AKTX technical analysis: range, last 7.63 USD, RSI 45.9, 52w range 6.91 USD–15.5 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is AKTX in?
Akari Therapeutics (AKTX) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is AKTX in an uptrend or downtrend?
As of 2026-10-26, AKTX is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is AKTX's trailing P/E ratio?
AKTX's trailing P/E is -0.01, with a market cap of 0.01B. See the earnings research page for full valuation detail.
When does AKTX next report earnings?
AKTX is next scheduled to report earnings on 2026-08-18.